Get to know our clinical trials
The study drug, dapagliflozin, also belongs to this class, and is recommended for the treatment of diabetes, renal and cardiovascular diseases
THIS STUDY AIMS TO CONFIRM THE EFFECTIVENESS OF SGLT2I MEDICATION FOR THEIR DISEASE.
Status
In recruitment
headquarters
Pamplona
Early phase
Technical Summary
- IN THIS STUDY, WE ARE EXAMINING THE EFFICACY OF THE DRUG DAPAGLIFLOZIN (FORXIGA®) IN PREVENTING RENAL AND HEART FAILURE. WE ARE ALSO INVESTIGATING THE TOLERABILITY AND SAFETY OF THIS DRUG. THEREFORE, WE COMPARE THE EFFECTS OF DAPAGLIFLOZIN WITH A PLACEBO. A PLACEBO IS A SUBSTANCE WITHOUT ACTIVE SUBSTANCE, A "DUMMY DRUG".
- Code EudraCT: 2021-005446-15
- Protocol number: 202100617
- Promoter: UMCG
- Molecule/Drug: Dapagliflozina
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.